enterocin has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buss, GP; Wilson, CM | 1 |
| Durdagi, S; Erol, I; Kotil, SE; Ortakci, F | 1 |
2 other study(ies) available for enterocin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Exploring the cytotoxic mechanisms of Pediocin PA-1 towards HeLa and HT29 cells by comparison to known bacteriocins: Microcin E492, enterocin heterodimer and Divercin V41.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Apoptosis; Bacteriocins; Bridged-Ring Compounds; Cell Survival; COVID-19; HeLa Cells; HT29 Cells; Humans; Models, Molecular; Pandemics; Pediocins; Protein Conformation; SARS-CoV-2; Sequence Homology, Amino Acid; Toll-Like Receptor 4 | 2021 |
Exploring the binding capacity of lactic acid bacteria derived bacteriocins against RBD of SARS-CoV-2 Omicron variant by molecular simulations.
Topics: Bacteriocins; COVID-19; COVID-19 Drug Treatment; Humans; Pediocins; Peptides; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2023 |